Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,068 across all filing types
Latest filing 2021-02-19 Earnings Release
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Earnings Release 2020
Earnings Release Classification · 99% confidence The document is titled "Bokslutskommuniké för det förkortade räkenskapsåret 1 maj – 31 december 2020" (Year-end report communication for the shortened fiscal year May 1 – December 31, 2020). It contains detailed financial figures for the third quarter and the shortened fiscal year, along with commentary from the CEO regarding business performance, strategy, pipeline development (Apealea®, Docetaxel micellar), and management changes. The content structure—key events, quarterly/period results, CEO commentary, and strategic review—is characteristic of a comprehensive financial report covering a specific period, but it is presented as a 'communication' or 'release' of the results rather than the full statutory filing (like a 10-K). Since it provides comprehensive financial results for a period shorter than a year (8 months), it aligns best with the definition of an Interim/Quarterly Report (IR). It is more detailed than a simple Earnings Release (ER) which usually contains only key highlights. Q3 2020
2021-02-19 Swedish
Earnings Release 2020
Earnings Release Classification · 99% confidence The document explicitly states it is a "Year-end report for the shortened financial year May 1, 2020 – December 31, 2020". It contains detailed financial figures for the third quarter and the full financial year, along with a CEO review discussing strategy, pipeline progress, and management changes. This structure and content strongly indicate a comprehensive annual or year-end financial report, which aligns with the definition of an Annual Report (10-K) or, given it's a non-US company reporting a year-end summary, potentially an Annual Report (AR) if 10-K is strictly for SEC filers. Since the definitions provided list 'Annual Report (Code: 10-K)' and 'Audit Report / Information (Code: AR)', and this document contains the full financial performance summary for the year, 10-K is the closest standard equivalent for a full annual report, although AR is also plausible if 10-K is reserved strictly for US SEC filings. Given the depth of financial data and the 'Year-end report' title, 10-K is the most appropriate classification for a comprehensive annual filing. FY 2020
2021-02-19 English
Oasmia’s partner Elevar Therapeutics signs licensing agreement with Inceptua Group for the commercialization of Apealea® (paclitaxel micellar) in Europe
Regulatory Filings Classification · 95% confidence The document is a press release dated December 28, 2020, announcing a significant business development: a licensing agreement between Oasmia's partner (Elevar Therapeutics) and Inceptua Group for the commercialization of a drug (Apealea®) in Europe. This type of announcement, detailing strategic partnerships, licensing deals, or major commercial milestones, typically falls under general corporate news or regulatory updates. Since it is not a formal financial report (10-K, IR, ER, MRQ), a management change (MANG), or a specific transaction like a share buyback (POS) or director dealing (DIRS), it best fits the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements that don't fit elsewhere, especially when related to market-moving news like licensing agreements. The document structure is that of a press release, not a formal SEC filing.
2020-12-28 English
Oasmias partner Elevar tecknar licensavtal med Inceptua Group för kommersialisering av Apealea® i Europa
M&A Activity Classification · 99% confidence The document is a press release dated December 28, 2020, announcing a licensing agreement between Oasmia's partner (Elevar Therapeutics) and Inceptua Group for the commercialization of the drug Apealea® in Europe. The text explicitly states that the information is 'such information as Oasmia Pharmaceutical is obliged to make public pursuant to the EU's Market Abuse Regulation' and includes contact information for investor relations. This structure strongly indicates a mandatory regulatory disclosure or a significant corporate event announcement. Since it details a major commercial/licensing deal, it falls under the category of a significant corporate action announcement. While it is a press release, the content is a major business development (licensing/commercialization agreement), which is often categorized under general corporate updates or regulatory filings if it's not a specific financial report (like 10-K or ER). Given the options, this is a significant corporate announcement that doesn't fit perfectly into the specific financial reporting codes (10-K, IR, ER) or specific corporate governance codes (MANG, DIRS). It is a major business development announcement. In the context of the provided definitions, 'Regulatory Filings' (RNS) serves as the general category for miscellaneous regulatory announcements that do not fit elsewhere, which is appropriate for a major, mandatory disclosure about a licensing deal under MAR. It is not a Call Transcript (CT), Earnings Release (ER), or a specific financial report (10-K, IR).
2020-12-28 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Oasmia Pharmaceutical AB covering the period from May 1 to October 31, 2020. It contains detailed financial statements, management commentary, business updates, and performance metrics for the second quarter and the six-month period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2021
2020-12-09 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the period May 1, 2020 – October 31, 2020' for Oasmia Pharmaceutical AB. It contains comprehensive financial data, including consolidated net sales, operating profit/loss, net profit/loss, and earnings per share for the second quarter and the six-month period. It also includes management commentary, business strategy, and operational updates. This fits the definition of an Interim/Quarterly Report (IR). H2 2020
2020-12-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.